Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck KGaA, Darmstadt, Germany, and Sanofi Genzyme.

Community Practice Connections™: 3rd Annual European Congress on Immunotherapies in Cancer™

Release Date: December 21, 2018
Expiration Date: December 21, 2019
Media: Internet - based

Activity Overview

This activity focuses on immunotherapies for cancers of the bladder, lung, and skin. It consists of a series of brief video interviews with leading experts and short summaries of clinical data related to issues discussed in the interviews. The content and videos are based on presentations given at the 3rd Annual European Congress on Immunotherapies in Cancer™, held September 21-22, 2018, in Barcelona, Spain. This program provides expert perspectives on current standards of care and emerging concepts in cancer immunotherapy, as well as practical guidance on how to integrate these therapeutics into your practice.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck KGaA, Darmstadt, Germany, and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is intended for medical oncologists and other healthcare professionals (eg, physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Evaluate the clinical applicability of data from clinical trials of immunotherapy strategies
  2. Discuss methods to individualize the use of immunotherapy strategies, including the use of biomarkers
  3. Describe how to proactively mitigate and manage adverse events associated with the use of treatment strategies used in the care of patients with cancer
  4. Identify unmet clinical needs in cancer treatment and highly anticipated clinical trials evaluating novel immunotherapeutic approaches

Faculty, Staff, and Planners' Disclosures


Joaquim Bellmunt, MD, PhD
Associate Professor of Medicine, Harvard Medical School
GU Oncology Research Coordinator PSMAR
Director, IMIM-Hospital del Mar Medical Research Institute
Barcelona, Spain

Disclosures: Grant/Research Support: Sanofi-Aventis, Novartis, Takeda, Pfizer; Consultant/Advisory Board: Genentech, Merck Sharp & Dohme, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Pierre Fabre, Sanofi-Aventis, Astellas, OncoGenex, Janssen

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine
Chief, Division of Medical Oncology, Department of Medicine
Deputy Director, Albert Einstein Cancer Center
Bronx, NY, USA

Disclosures: Grant/Research Support: National Cancer institute; Consultant/Advisory Board: GlaxoSmithKline, AstraZeneca, Clovis, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero; Shareholder: Adgero, Stelexis

Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Chair, Melanoma Committee at SWOG
Los Angeles, CA, USA

Disclosures: Consultant/Advisory Board: Amgen, Bristol-Myers Squibb, Chugai, Genentech, Merck, Novartis, Roche; Shareholder: Advaxis, Arcus, BiOncotech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, IsoPlexis, Rgenix, Lutris, PACT, Tango, Kite Pharma

Caroline Robert, MD, PhD
Head of the Dermatology Unit
Department of Medicine
Gustave Roussy and Paris-Sud University
Villejuif Grand - Paris, France

Disclosures: Consultant/Advisory Board: Bristol-Myers Squibb, Novartis, Roche, Amgen, Merck, Pierre Fabre

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By